Table 70: Likar 2008[288]

Study	Likar 2008[288]
Study type	RCT (Patient randomised; Parallel).
Number of studies (number of participants)	Single centre (n=13)
Countries and setting	Conducted in Germany; Setting: Hospital.
Line of therapy	Not applicable.
Duration of study	Intervention time: 12 hours.
Method of assessment of guideline condition	Unclear method of assessment/diagnosis.
Stratum	Overall.
Subgroup analysis within study	Not applicable.
Inclusion criteria	Semi-conscious or unconscious people with advanced terminal cancer with predicted life expectancy of 3 days or less.
Exclusion criteria	Fully conscious people with a life expectancy of more than 3 days or people who are already receiving a drug from the

	same drug class.
Age, gender and ethnicity	Age - Mean (SD): Glycopyrronium bromide 72 (standard error 5); Hyoscine hydrobromide 71 (standard error 4). Gender (M:F): 10/3. Ethnicity:
Indirectness of population	No indirectness.
Interventions	(n=6) Intervention 1: Anti-muscarinic - Glycopyrronium bromide. Glycopyrronium bromide 0.4 mg every 6 hours intravenously. Duration Every 2 hours up to 12 hours. Concurrent medication/care: The use of analgesics/sedatives was documented. (n=7) Intervention 2: Anti-muscarinic - Hyoscine hydrobromide. Hyoscine hydrobromide 0.5 mg every 6 hours intravenously. Duration Every 2 hours up to 12 hours. Concurrent medication/care: The use of analgesics/sedatives was documented.
Funding	Other (It was described that the authors have no conflicts of interest.)

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: GLYCOPYRRONIUM BROMIDE versus HYOSCINE HYDROBROMIDE

Protocol outcome 1: Subjective or objective improvement in respiratory secretions at hours/days
- Actual outcome: Death rattle assessed using scale of 1 to 5: 1 = noisy breathing; 2 = minimal rattle; 3 = moderate rattle; 4 = severe rattle; 5 = very severe rattle at Measured every 2 hours up to 12 hours; Risk of bias: High; Indirectness of outcome: No indirectness.

Protocol outcome 2: Adverse events (particularly paradoxical agitation, failure to expectorate, dry mouth at hours/days
- Actual outcome: Pain: 1 = slight; 2 = moderate; 3 = severe at Measured every 2 hours up to 12 hours; Other: It is only described that the percentage of people with pain in each group was not different between groups (no p-value or graph provided); Risk of bias: High; Indirectness of outcome: No indirectness.
- Actual outcome: Restlessness: 1 = slight; 2 = moderate; 3 = severe at Measured every 2 hours up to 12 hours; Other: It is described that the incidence of restlessness was not statistically different between groups.; Risk of bias: High; Indirectness of outcome: No indirectness.

Protocol outcomes not reported by the study	Quality of life at hours/days; Hospitalisation at hours/days; Subjective ratings from people on distress related to noisy breathing /respiratory secretions at hours/days; Sedation (patient-rated, clinician-rated, carer-rated) at hours/days; Subjective ratings from informal carers' on distress relating to noisy breathing/respiratory secretions at hours/days; Hydration status at hours/days; Length of survival at hours/days; Length of stay at hours/days.